Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells.
about
MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptorLINE-1 ORF-1p enhances the transcription factor activity of pregnenolone X receptor and promotes sorafenib resistance in hepatocellular carcinoma cellsMicroRNA-645 targets urokinase plasminogen activator and decreases the invasive growth of MDA-MB-231 triple-negative breast cancer cells
P2860
Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Novel ADAM-17 inhibitor ZLDI-8 ...... epatocellular carcinoma cells.
@en
Novel ADAM-17 inhibitor ZLDI-8 ...... epatocellular carcinoma cells.
@nl
type
label
Novel ADAM-17 inhibitor ZLDI-8 ...... epatocellular carcinoma cells.
@en
Novel ADAM-17 inhibitor ZLDI-8 ...... epatocellular carcinoma cells.
@nl
prefLabel
Novel ADAM-17 inhibitor ZLDI-8 ...... epatocellular carcinoma cells.
@en
Novel ADAM-17 inhibitor ZLDI-8 ...... epatocellular carcinoma cells.
@nl
P2093
P2860
P1476
Novel ADAM-17 inhibitor ZLDI-8 ...... epatocellular carcinoma cells.
@en
P2093
Huiwei Sun
Qingchun Zhao
Qiyu Jiang
Ruichuang Yang
Shuang Cao
Tianshu Ren
Xiaojuan Li
P2860
P2888
P356
10.1038/S41419-018-0804-6
P577
2018-07-03T00:00:00Z
P6179
1105270475